| Good Samaritan Society - Moscow Village | |
| 640 North Eisenhower Street, Moscow, Idaho 83843 | |
| (208) 882-6560 | |
| Name | Good Samaritan Society - Moscow Village |
|---|---|
| Location | 640 North Eisenhower Street, Moscow, Idaho |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 64 |
| Occupancy Rate | 65.63% |
| Medicare ID (CCN) | 135067 |
| Legal Business Name | The Evangelical Lutheran Good Samaritan Society |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1598755266 |
| Organization Name | THE EVANGELICAL LUTHERAN GOOD SAMARITAN SOCIETY |
| Doing Business As | GOOD SAMARITAN SOCIETY - MOSCOW VILLAGE |
| Address | 640 N Eisenhower St, Moscow, ID 83843 |
| Phone Number | 208-882-6560 |
News Archive
The technical issue with the second stage of the Dnepr rocket that delayed the launch of ESA's Earth Explorer CryoSat-2 satellite in February has now been resolved - and the new launch date of 8 April has been set.
Metabolic and anxiety-related disorders both pose a significant healthcare burden, and are in the spotlight of contemporary research and therapeutic efforts. Although intuitively we assume that these two phenomena overlap, the link has not been proven scientifically.
Following the recent publication of a study in the New England Journal of Medicine that further confirms the elevated risk of in-hospital death amongst COVID-19 patients with concomitant cardiovascular disease;
AliveCor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company clearance for its algorithm to detect atrial fibrillation (AFib), the most common form of cardiac arrhythmia.
› Verified 4 days ago
| NPI Number | 1811614332 |
| Organization Name | MOSCOW NORTH OF CASCADIA, LLC |
| Doing Business As | PARADISE CREEK HEALTH AND REHABILITATION OF CASCADIA |
| Address | 640 N Eisenhower St, Moscow, ID 83843 |
| Phone Number | 208-401-9500 |
News Archive
The technical issue with the second stage of the Dnepr rocket that delayed the launch of ESA's Earth Explorer CryoSat-2 satellite in February has now been resolved - and the new launch date of 8 April has been set.
Metabolic and anxiety-related disorders both pose a significant healthcare burden, and are in the spotlight of contemporary research and therapeutic efforts. Although intuitively we assume that these two phenomena overlap, the link has not been proven scientifically.
Following the recent publication of a study in the New England Journal of Medicine that further confirms the elevated risk of in-hospital death amongst COVID-19 patients with concomitant cardiovascular disease;
AliveCor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company clearance for its algorithm to detect atrial fibrillation (AFib), the most common form of cardiac arrhythmia.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The technical issue with the second stage of the Dnepr rocket that delayed the launch of ESA's Earth Explorer CryoSat-2 satellite in February has now been resolved - and the new launch date of 8 April has been set.
Metabolic and anxiety-related disorders both pose a significant healthcare burden, and are in the spotlight of contemporary research and therapeutic efforts. Although intuitively we assume that these two phenomena overlap, the link has not been proven scientifically.
Following the recent publication of a study in the New England Journal of Medicine that further confirms the elevated risk of in-hospital death amongst COVID-19 patients with concomitant cardiovascular disease;
AliveCor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company clearance for its algorithm to detect atrial fibrillation (AFib), the most common form of cardiac arrhythmia.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 12.82 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.2 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 63.38 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.72 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 8.4 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.55 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 97.16 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 7.09 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 69.7 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 21.01 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 6.3 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 3.74 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 82.32 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 84.85 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 28.67 | 82.93 |
News Archive
The technical issue with the second stage of the Dnepr rocket that delayed the launch of ESA's Earth Explorer CryoSat-2 satellite in February has now been resolved - and the new launch date of 8 April has been set.
Metabolic and anxiety-related disorders both pose a significant healthcare burden, and are in the spotlight of contemporary research and therapeutic efforts. Although intuitively we assume that these two phenomena overlap, the link has not been proven scientifically.
Following the recent publication of a study in the New England Journal of Medicine that further confirms the elevated risk of in-hospital death amongst COVID-19 patients with concomitant cardiovascular disease;
AliveCor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company clearance for its algorithm to detect atrial fibrillation (AFib), the most common form of cardiac arrhythmia.
› Verified 4 days ago
Good Samaritan Society - Moscow Village Location: 640 North Eisenhower Street, Moscow, Idaho 83843 Phone: (208) 882-6560 | |